Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin dose-effect study in SGLT-2 inhibitor-associated diabetic ketoacidosis
ChiCTR2200059377Phase 4Recruiting
- Sponsor
- Rongxian People's Hospital
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of human insulin in diabetic ketoacidosis (DKA) (3 arms), sponsored by Rongxian People's Hospital. Primary endpoints: Heart rate, Mean arterial pressure and 8 more. Started Mar 2022; status: recruiting.
02
Drugs
human insulin
03
Conditions
diabetic ketoacidosis (DKA)
Beyond the preview
Go deeper on ChiCTR2200059377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059377.